BI 836880 / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 836880 / Boehringer Ingelheim
2018-002344-81: Platform trial evaluating safety and efficacy of BI 754091 anti- PD-1 based combination therapies in PD-(L)1 naïve and PD- (L)1 pretreated patient populations with advanced/metastatic solid tumours

Not yet recruiting
2
260
Europe
BI 754091, BI 754111, BI 836880, BI 754091, BI 754111, BI 836880, Solution for infusion
Boehringer Ingelheim Limited, Boehringer Ingelheim
Advanced/metastatic solid tumours, Advanced solid tumours, Diseases [C] - Cancer [C04]
 
 
NCT03697304: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Active, not recruiting
2
212
Europe, Canada, US
BI 754091, ezabenlimab, BI 754111, BI 836880
Boehringer Ingelheim
Neoplasm Metastasis
05/25
05/25
2017-001221-40: A study to test different doses of BI 836880 in patients with an eye disease called wet age-related macular degeneration (wAMD)

Not yet recruiting
1/2
42
Europe
BI 836880, Solution for injection
Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG
wet age-related macular degeneration (wAMD), eye disease called wet age-related macular degeneration (wAMD)SRD part, MRD cohort1: treatment-resistant patientsMRD cohort2: treatment-naive patientsMRD cohort3: frequently treated patients, Diseases [C] - Eye Diseases [C11]
 
 
NCT03861234: A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Completed
1/2
43
Europe, US
BI 836880
Boehringer Ingelheim
Wet Macular Degeneration
11/23
11/23
NCT03468426: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Completed
1
252
Europe, US, RoW
BI 836880, ezabenlimab, BI 754091
Boehringer Ingelheim
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
07/24
09/24
NCT05249426: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruiting
1
48
Europe, Japan, US, RoW
BI 765063, Ezabenlimab, BI 754091, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/24
08/25

Download Options